- Home
- NAMS vs TLX Comparison
NAMS vs TLX Comparison
Compare NAMS & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- TLX
- Stock Information
- Founded
- NAMS 2019
- TLX 2015
- Country
- NAMS Netherlands
- TLX Australia
- Employees
- NAMS N/A
- TLX N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- NAMS Health Care
- TLX Health Care
- Exchange
- NAMS Nasdaq
- TLX Nasdaq
- Market Cap
- NAMS 3.1B
- TLX 3.0B
- IPO Year
- NAMS N/A
- TLX N/A
- Fundamental
- Price
- NAMS $40.29
- TLX $9.61
- Analyst Decision
- NAMS Strong Buy
- TLX Strong Buy
- Analyst Count
- NAMS 10
- TLX 4
- Target Price
- NAMS $44.80
- TLX $21.00
- AVG Volume (30 Days)
- NAMS 1.0M
- TLX 82.3K
- Earning Date
- NAMS 11-05-2025
- TLX 01-01-0001
- Dividend Yield
- NAMS N/A
- TLX N/A
- EPS Growth
- NAMS N/A
- TLX N/A
- EPS
- NAMS N/A
- TLX 0.04
- Revenue
- NAMS $35,243,000.00
- TLX $664,225,558.00
- Revenue This Year
- NAMS N/A
- TLX N/A
- Revenue Next Year
- NAMS N/A
- TLX N/A
- P/E Ratio
- NAMS N/A
- TLX $226.08
- Revenue Growth
- NAMS 4.91
- TLX 55.35
- 52 Week Low
- NAMS $14.06
- TLX $8.76
- 52 Week High
- NAMS $41.47
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- NAMS 61.84
- TLX 47.72
- Support Level
- NAMS $36.59
- TLX $8.76
- Resistance Level
- NAMS $40.88
- TLX $9.40
- Average True Range (ATR)
- NAMS 2.59
- TLX 0.25
- MACD
- NAMS -0.09
- TLX -0.04
- Stochastic Oscillator
- NAMS 90.44
- TLX 59.07
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.